h
Let’s Work Together
arrosa@select.com

Meet Arrosa, the perfect theme to elevate your online presentation with.

Search here!
Ander Pino

Ander Pino

Doutor em Biotecnologia

Investigador no Laboratório de I&D de medicina regenerativa.

Licenciado em Biotecnologia

Doutorado em investigação e avaliação de drogas. (UPV-EHU)

CUM LAUDE e Menção de Prémio Extraordinário: Terapias autologas em Dermatologia Regenerativa

Mestrado em Investigação social da comunicação científica. (Universidade Internacional de Valência)

Licenciatura em Biotecnologia (Universidade de León)

Licenciatura em Biotecnologia (Universidade de Vermont)

Investigador do Laboratório de Medicina Regenerativa de I&D

Responsável pela formação em medicina regenerativa

Professor de Terapia Regenerativa Oral do Mestrado e Reabilitação Implantológica Oral

Artigos publicados

Skin injury and wound healing is an inevitable event during lifetime. However, several complications may hamper the regeneration of the cutaneous tissue and lead to a chronic profile that prolongs patient recovery. Platelet-rich plasma is rising as an effective and safe alternative to the management of wounds

Over the last three decades, there has been special interest in developing drugs that mimic the characteristics of natural tears for use it in the treatment of several ocular surface disorders. Interestingly, the composition of blood plasma is very similar to tears. Therefore, different blood-derived products like autologous serum (AS) and plasma rich in growth factors (PRGF) have been developed for the treatment of diverse ocular pathologies.

Cutaneous autoimmune and inflammatory diseases are a major burden of global disease and many lack effective treatments that can derive in different dermatoses like atopic dermatitis. Despite the increase prevalence and the high health-care costs worldwide, the heterogeniety and multifactoriality of these diseases mean that effective treatment options are scarce.